{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 56 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'R17-1399', 'Guidance for industry: M3(R2) nonclinical safety studies for the conduct of', 'human clinical trials andmarketing authorization for pharmaceuticals', '(January 2010, ICH, revision 1).', 'https://www.fda.gov/downloads/guidances/ucm073246.pdf (access date 18', 'April 2017); U.S. Department of Health and Huma Services, Food and', 'Drug Administration, Center for Drug Evaluation and Research (CDER),', 'Center for Biologics Evaluation and Research (CBER) (2010)', 'R18-1289', 'Ofev (nintedanib) capsules, for oral use (Boehringer Ingelheim', 'Pharmaceuticals) (U.S. prescribing information, revised: 1/2018).', 'R18-1704', 'Dowman L, Hill CJ, Holland Pulmonary rehabilitation for interstitial lung', 'disease (review). Cochrane Database Syst Rev (10), CD006322 (2014).', 'R18-1767', 'Nathan S, Albera C, du Bois R, Bradford W, Costabel U, King T, et. Al, 6-', 'minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis', '(IPF): Confirmation of the minimal clinically important difference', '(MCID). European Respiratory Journal 40. Suppl 56 (2012): P3656.', '9.2', 'UNPUBLISHED REFERENCES', 'c02155574-02', 'A 52 weeks, double blind, randomized, placebo-controlled trial evaluating', 'the effect of oral BiBF 1120, 150 mg twice daily, on an annual Forced Vital', 'Capacity decline, in patients with Idopathic Pulmonary Fibrosis (IPF) 08', 'Apr 2014.', 'c02098775-02', 'A 52 weeks, double blind, randomized, placebo-controlled trial evaluating', 'the effect of oral BiBF 1120, 150 mg twice daily, on an annual Forced Vital', 'Capacity decline, in patients with Idopathic Pulmonary Fibrosis (IPF) 08', 'Apr 2014.', 'U07-1248-07', \"Investigator's brochure: BIBF 1120, Indication: Idiopathic\", 'Pulmonary Fibrosis. 1199.P3. Version 7. 09 Dec 2011.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 57 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '10.', 'APPENDICES', '10.1', 'EXERCISE TESTING INCLUDING 6 MINUTE WALK TEST AND', 'WORK CYCLE ERGOMETRY', 'To supplement the information on the Six Minute Walk Test described in this section,', 'instructions and an instructional video has been developed. More detailed information on the', 'procedure, on staffing, site and equipment requirements, patient preparation, IC', 'measurements, and calculations etc. can be found in the instructions, which is filed in the ISF.', '10.1.1', 'General considerations for 6MWT and exercise testing', 'Exercise performance variability', 'A number of physiological and psychological factors are known to affect exercise', 'performance. Lack of attention to controlling these extraneous factors may result in an', 'unacceptable degree of variability in exercise performance. As such, certain requirements', 'have been put in place to reduce exercise performance variability:', 'Physiological:', 'Pre-exercise diet: Subjects are to be encouraged to eat breakfast before coming to the clinic.', 'However, subjects should not eat within 2 hours of exercise tests.', 'Hydration state: Subjects are to be encouraged to maintain an adequate hydration state during', 'the morning of the exercise tests (i.e., drink lots of water).', 'Environmental conditions (temperature, humidity): Temperature and humidity within the', 'laboratory should be at comfortable levels, and should be recorded each testing day.', 'Previous exercise:', 'Fatigue: Subjects should be encouraged to stay well-rested and to refrain from any strenuous,', 'fatiguing or exhausting activities (e.g., walking up hills, walking up many flights of stairs,', 'running, cycling, shovelling snow, strenuous household chores) on the morning of exercise', 'tests.', 'Delayed onset muscular soreness (DOMS): Very strenuous, heavy type of activities,', 'especially activities to which the subject is unaccustomed, can lead to muscle soreness 24-48', 'hours after the activity. Subjects should be encouraged to refrain from any type of heavy', 'lifting, exhaustive digging in the garden etc., for 2-3 days prior to each clinic visit, especially', 'if the subject has not performed these activities recently.', 'Psychological:', 'External motivational cues: motivational cues provided to the subject can have profound', 'effects on exercise performance. It is imperative that external motivational cues are', 'controlled across subjects and across sites.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}